Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Eli Lilly to buy Boston's Kelonia for up to $7 billion in cancer push
By Siddhi Mahatole April 20 (Reuters) - U.S. drugmaker Eli Lilly will buy privately held biotech firm Kelonia Therapeutics for up to $7 billion, gaining access to experimental cancer treatments as it ...
Hosted on MSN
Lilly to acquire cancer drug developer Kelonia for up to $7B
Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...
Lilly to buy Kelonia Therapeutics for up to $7 billion to boost cancer pipeline
April 20 (Reuters) - U.S. drugmaker Eli Lilly has agreed to buy privately held biotech firm Kelonia Therapeutics for up to $7 billion, the companies said on Monday, gaining access to experimental ...
GEN
Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline
Eli Lilly researchers at work. Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, the companies said today, in a deal that would bolster the buyer’s oncology pipeline with an early ...
The Boston Globe
Lilly to buy Boston biotech Kelonia for $3.25 billion in latest Mass. investment
Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...
U.S. News & World Report
Eli Lilly to Buy Boston's Kelonia for up to $7 Billion in Cancer Push
April 20 (Reuters) - U.S. drugmaker Eli Lilly ⁠will ⁠buy privately held biotech firm ⁠Kelonia Therapeutics for up to $7 billion, gaining access to experimental cancer treatments as it bolsters its ...